When Abby Govindan steps onto a Houston stage, her comedy is intertwined with Texas, just like she is. "My heart beats for ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Eli Lilly’s shares surged more than 14% at the time, one of the company’s largest single-day gains in the last five years.

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...

Lilly's late-stage results for its experimental oral obesity drug raised concerns.

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than expected Q2 results. Read more here.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly plans to move to a second Phase III trial for its oral GLP-1, while Novo Nordisk’s pill version of Wegovy also continues its path toward FDA approval.

Lilly plans to sell its production site in Branchburg, New Jersey, as part of a broader production overhaul at the company, a spokesperson confirmed.

Alexa Bliss has been back in WWE for several months now, but fans have yet to see the full return of the twisted Bliss that took a hiatus from the company follo ...

A trial of Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine ...